Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 12/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | HCK | P08631 | 6/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12288408 | 0.90 | HCK (0.55) | NR3C2MAPK14HCKMAPK12 | |
| SCHEMBL2405921 | 0.85 | MAPK14 (0.51) | NR3C2MAPK14HCKMAPK12TNF | |
| SCHEMBL1978082 | 0.84 | MAPK14 (0.48) | NR3C2MAPK14HCKMAPK12TNF | |
| SCHEMBL1978086 | 0.84 | MAPK14 (0.48) | NR3C2MAPK14HCKMAPK12TNF | |
| SCHEMBL12320309 | 0.83 | GPR84 (0.39) | NR3C2MAPK14HCKMAPK12CNR1 | |
| SCHEMBL1981716 | 0.83 | NR3C2 (0.50) | NR3C2MAPK14HCKMAPK12 | |
| SCHEMBL2311222 | 0.83 | NR3C2 (0.49) | NR3C2MAPK14HCKMAPK12 | |
| SCHEMBL13331029 | 0.80 | GCK (0.49) | MAPK14HCKMAPK12 | |
| SCHEMBL2558223 | 0.79 | CNR1 (0.40) | NR3C2MAPK14HCKMAPK12CNR1 | |
| SCHEMBL12596117 | 0.79 | HCK (0.46) | MAPK14HCKMAPK12CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-8975285-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2014-04-24 | — | — | US | disclosed |
| EP-2350049-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-02-26 | — | — | EP | disclosed |
| US-8618140-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20130012512-A1 | P38 MAP kinase inhibitors | ITO KAZUHIRO (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8293748-B2 | p38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-23 | — | — | US | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2350049-A2 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | NR3C2 254/4885MAPK14 10/4885HCK 348/4885 |
| US-20130012512-A1 | P38 MAP kinase inhibitors | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885MAPK14 33/4885HCK 2830/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885MAPK14 33/4885HCK 2830/4885 |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885MAPK14 33/4885HCK 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.